A Multidisciplinary Approach to Checkpoint Inhibitor Adverse Reactions

Area of Science:

• Oncology
• Immunology
• Allergy

Background:

• Immune checkpoint inhibitors (ICIs) offer durable cancer treatment responses for many patients.
• Immune-related adverse events (irAEs) are a significant clinical challenge associated with ICIs, impacting various organ systems.
• irAEs can lead to treatment interruption, morbidity, and mortality, necessitating careful management.

Purpose of the Study:

• To review clinically significant immune-related adverse events associated with immune checkpoint inhibitors.
• To highlight key principles for the multidisciplinary diagnosis and management of irAEs.
• To provide guidance for allergist-immunologists in optimizing patient outcomes during ICI therapy.

Main Methods:

• Literature review of immune checkpoint inhibitors and their associated adverse events.
• Synthesis of current clinical practices for irAE identification and evaluation.
• Focus on multidisciplinary team approaches for irAE management.

Main Results:

• ICIs are associated with a broad spectrum of irAEs affecting virtually all organ systems.
• Early recognition and prompt, multidisciplinary management are essential for mitigating irAE complications.
• Effective irAE management is critical for maintaining immunotherapy continuity and improving patient survival.

Conclusions:

• Immune-related adverse events are a critical consideration in cancer immunotherapy with ICIs.
• A well-informed, multidisciplinary approach is paramount for the successful diagnosis and management of irAEs.
• Allergist-immunologists play a key role in managing irAEs to optimize patient outcomes and facilitate ongoing cancer treatment.